Home » Stocks » Xenetic Biosciences

Xenetic Biosciences, Inc. (XBIO)

Stock Price: $1.23 USD 0.08 (6.96%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 7.73M
Revenue (ttm) 73,815
Net Income (ttm) -12.63M
Shares Out 6.28M
EPS (ttm) -3.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $1.23
Previous Close $1.15
Change ($) 0.08
Change (%) 6.96%
Day's Open 1.17
Day's Range 1.13 - 1.24
Day's Volume 244,489
52-Week Range 0.44 - 2.51

More Stats

Market Cap 7.73M
Enterprise Value n/a
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 6.28M
Float 5.28M
EPS (basic) -1.68
EPS (diluted) -3.33
FCF / Share -0.99
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 349,915
Short Ratio 0.85
Short % of Float 6.50%
Beta 2.48
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 104.73
PB Ratio 0.45
Revenue 73,815
Operating Income -12.79M
Net Income -12.63M
Free Cash Flow -6.15M
Net Cash 9.37M
Net Cash / Share 1.49
Gross Margin 23.12%
Operating Margin -17,327.72%
Profit Margin -19,009.90%
FCF Margin -8,325.68%
ROA -28.34%
ROE -91.11%
ROIC -7,501.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.23
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--152.83%---240.6%-
Gross Profit0.02-7.433.00--1.000.25
Operating Income-12.89-7.28-3.57-47.43-9.82-12.92-8.55-6.34
Net Income-12.78-7.30-3.60-54.21-12.51-14.31-8.58-6.33
Shares Outstanding2.850.760.720.620.350.340.300.30
Earnings Per Share-6.33-9.66-4.92-94.08-35.52-43.57-27.72-19.80
Operating Cash Flow-6.40-6.461.49-8.79-5.30-12.68-6.05-6.26
Capital Expenditures-0.02-0.01-0.020.01-0.05-0.08-0.09
Free Cash Flow-6.40-6.441.48-8.80-5.29-12.74-6.13-6.35
Cash & Equivalents10.370.645.604.110.202.574.9111.14
Total Debt----4.050.400.680.68
Net Cash / Debt10.370.645.604.11-3.852.184.2210.45
Book Value17.219.9114.3016.176.6110.4812.6220.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xenetic Biosciences, Inc.
Country United States
Employees 4
CEO Jeffrey F. Eisenberg

Stock Information

Ticker Symbol XBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XBIO


Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.